Payment overview · 2025
General Payments
$1,753.03
85 reported records · 16 companies
Healthcare provider profile · identity verified
Samir Al-Kabbani, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · KNOXVILLE, TN · NPI 1083681183
Verified facts
What the public records show
CMS Open Payments records show Samir Al-Kabbani, MD received $1,753.03 in general payments during 2025 across 85 reported records.
Neurelis, Inc. accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Tysabri, Valtoco.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tysabri by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Valtoco by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$391.47 | 22.3% | 12 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $324.58 | 18.5% | 15 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $179.88 | 10.3% | 11 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$153.23 | 8.7% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $138.85 | 7.9% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $108.06 | 6.2% | 6 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $93.18 | 5.3% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $92.01 | 5.2% | 5 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $69.47 | 4.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.64 | 2.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $36.74 | 2.1% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $35.89 | 2.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $32.99 | 1.9% | 2 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.14 | 1.1% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $18.09 | 1.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $15.81 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,753.03 | 85 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $391.47 | 12 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $228.49 | 10 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $138.85 | 6 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $126.57 | 8 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $113.38 | 7 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $108.06 | 6 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $96.09 | 5 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $93.18 | 5 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $92.01 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $73.89 | 4 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $52.07 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $42.64 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $36.74 | 2 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $35.00 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $32.99 | 2 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 39 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 94 | exact normalized | Medicare Part D |
| TYSABRI tysabri |
2025 | Tysabri | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
39 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
94 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 627 | 128 |
| Gabapentin | Gabapentin | 576 | 95 |
| Lacosamide | Lacosamide | 488 | 78 |
| Lamotrigine | Lamotrigine | 300 | 54 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 195 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 193 | 34 |
| Topiramate | Topiramate | 180 | 32 |
| Aptiom | Eslicarbazepine Acetate | 175 | 24 |
| Pregabalin | Pregabalin | 155 | 25 |
| Clonazepam | Clonazepam | 124 | 27 |
| Fycompa | Perampanel | 112 | 13 |
| Phenobarbital | Phenobarbital | 106 | 19 |
| Briviact | Brivaracetam | 94 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 93 | 17 |
| Carbamazepine | Carbamazepine | 88 | 17 |
| Zonisamide | Zonisamide | 87 | 14 |
| Epidiolex | Cannabidiol (Cbd) | 85 | suppressed |
| Vimpat | Lacosamide | 83 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 82 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 67 | 15 |
| Oxcarbazepine | Oxcarbazepine | 65 | 18 |
| Teriflunomide | Teriflunomide | 63 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 62 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 62 | 17 |
| Meloxicam | Meloxicam | 55 | 12 |
| Clobazam | Clobazam | 51 | suppressed |
| Keppra Xr | Levetiracetam | 50 | suppressed |
| Levetiracetam Er | Levetiracetam | 48 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 47 | suppressed |
| Baclofen | Baclofen | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | 11 |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Keppra | Levetiracetam | 42 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 42 | suppressed |
| Lamotrigine Er | Lamotrigine | 40 | suppressed |
| Botox | Onabotulinumtoxina | 39 | 17 |
| Carbamazepine Er | Carbamazepine | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Acetazolamide | Acetazolamide | 30 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 28 | suppressed |
| Modafinil | Modafinil | 28 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 25 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 25 | suppressed |
| Lamictal | Lamotrigine | 25 | suppressed |
| Xcopri | Cenobamate | 24 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Kesimpta Pen | Ofatumumab | 22 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Lamictal Xr | Lamotrigine | 13 | suppressed |
| Tysabri | Natalizumab | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 12 | suppressed |
| Banzel | Rufinamide | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Depakote Er | Divalproex Sodium | 12 | suppressed |
| Furosemide | Furosemide | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Rufinamide | Rufinamide | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Topamax | Topiramate | 11 | suppressed |
| Valtoco | Diazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,753.03 · 85 records | Neurelis, Inc. | BOTOX, Bafiertam, Briviact, ELYXYB - CELECOXIB, INGREZZA, KESIMPTA, Motpoly XR, Nayzilam, Ocrevus Zunovo, QULIPTA, TYSABRI, Tascenso ODT, UPLIZNA, VALTOCO, VUMERITY, VYEPTI, WAINUA, ZTLido | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error